{
    "clinical_study": {
        "@rank": "70464", 
        "acronym": "PINNACLE", 
        "arm_group": [
            {
                "arm_group_label": "OMP-59R5 Combination with Etoposide and Cisplatin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Etoposide and Cisplatin plus Placebo", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The study consists of a Phase1b lead-in portion to determine the MTD of OMP-59R5 in\n      combination with EP for 6 cycles followed a Phase 2, multicenter, randomized,\n      placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with\n      EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in\n      subjects receiving first-line therapy for extensive stage small cell lung cancer."
        }, 
        "brief_title": "A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IV Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following criteria to be eligible for the study:\n\n          1. Histologically or cytologically documented extensive stage small cell lung cancer.\n\n          2. Adults of 18 years of age or older.\n\n          3. Performance Status (ECOG) of 0 or 1.\n\n          4. FFPE tumor tissue.\n\n          5. Adequate organ function:\n\n               1. Adequate hematologic function (absolute neutrophil count [ANC] \u2265 1,500 cells/\u03bcL;\n                  hemoglobin \u2265 9 g/dL, platelets \u2265 100,000/\u03bcL).\n\n               2. Adequate renal function (serum creatinine \u2264 1.5 mg/dL or calculated creatinine\n                  clearance \u2265 60 mL/min using Cockcroft-Gault formula).\n\n               3. Adequate hepatic function (alanine aminotransferase [ALT] \u2264 3 x upper limit of\n                  normal [ULN], ALT may be \u2264 5 x ULN if due to liver metastases but cannot be\n                  associated with concurrent elevated bilirubin >1.5xULN unless it is approved by\n                  the Sponsor's Medical Monitor).\n\n               4. Prothrombin Time (PT)/International Normalized Ration (INR) \u22641.5 \u00d7 ULN,\n                  activated partial thromboplastin time (aPTT) \u22641.5 \u00d7 ULN.\n\n          6. Written consent on an IRB/IEC-approved Informed Consent Form prior to any\n             study-specific evaluation.\n\n          7. For women of child-bearing potential, negative serum pregnancy test at screening and\n             use of physician-approved method of birth control from 30 days prior to the first\n             study drug administration to 30 days following the last study drug administration or\n             the last EP in the study, whichever is discontinued last.\n\n          8. Male subjects must be surgically sterile or must agree to use physician-approved\n             contraception during the study and for 30 days following the last study drug\n             administration or the last EP in the study, whichever is discontinued last.\n\n        Exclusion Criteria:\n\n        Subjects who meet any of the following criteria will not be eligible for participation in\n        the study:\n\n          1. Limited stage small cell lung cancer appropriate for radical treatment with\n             chemoradiation.\n\n          2. Prior therapy including radiation, chemotherapy or surgery for newly diagnosed\n             extensive stage small cell lung cancer.\n\n          3. Presence of any serious or uncontrolled illness including, but not limited to:\n             ongoing or active infection, symptomatic congestive heart failure unstable angina\n             pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis,\n             symptomatic pulmonary embolism, and psychiatric illness that would limit compliance\n             with study requirement.\n\n          4. History of myocardial infarction, acute coronary syndromes (including unstable\n             angina), coronary angioplasty and/or stenting within 6 months prior to the first\n             administration of study drug.\n\n          5. A history of malignancy with the exception of:\n\n               1. Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or\n                  in situ cervical cancer\n\n               2. Adequately treated stage I cancer from which the subject is currently in\n                  remission, or\n\n               3. Any other cancer from which the subject has been disease-free for \u2265 3 years\n\n          6. Known human immunodeficiency virus (HIV) infection.\n\n          7. Females who are pregnant or breastfeeding.\n\n          8. Concurrent use of therapeutic warfarin (prophylactic low dose of warfarin, i.e., 1 mg\n             daily for port catheter is allowed)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859741", 
            "org_study_id": "59R5-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "OMP-59R5 Combination with Etoposide and Cisplatin", 
                    "Etoposide and Cisplatin plus Placebo"
                ], 
                "description": "OMP-59R5 administered intravenously", 
                "intervention_name": "OMP-59R5", 
                "intervention_type": "Drug", 
                "other_name": "OMP-59R5"
            }, 
            {
                "arm_group_label": [
                    "OMP-59R5 Combination with Etoposide and Cisplatin", 
                    "Etoposide and Cisplatin plus Placebo"
                ], 
                "description": "administered intravenously", 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug", 
                "other_name": "Etoposide"
            }, 
            {
                "arm_group_label": [
                    "OMP-59R5 Combination with Etoposide and Cisplatin", 
                    "Etoposide and Cisplatin plus Placebo"
                ], 
                "description": "administered IV", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }, 
            {
                "arm_group_label": [
                    "OMP-59R5 Combination with Etoposide and Cisplatin", 
                    "Etoposide and Cisplatin plus Placebo"
                ], 
                "description": "administered intravenously", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Cisplatin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide phosphate", 
                "Cisplatin", 
                "Etoposide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Newly diagnosed Stage IV Small Cell Lung Cancer", 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jonilyn.brown@cshs.org", 
                    "last_name": "Jonilyn Brown", 
                    "phone": "310-652-3110"
                }, 
                "contact_backup": {
                    "email": "cynthia.martin@cshs.org", 
                    "last_name": "Cindi Martin", 
                    "phone": "(310) 423-2276"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars-Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Alain Mita, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robert M. Jotte, MD, PhD", 
                    "phone": "303-388-4876"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Rocky Mountain Cancer Centers"
                }, 
                "investigator": {
                    "last_name": "Robert Jotte, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "llhart@flcancer.com", 
                    "last_name": "Lowell L. Hart, M.D., F.A.C.P.", 
                    "phone": "239-938-0800"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33905"
                    }, 
                    "name": "Florida Cancer Specialists & Research Institute"
                }, 
                "investigator": {
                    "last_name": "Lowell L. Hart, M.D., F.A.C.P.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patelp6@mskcc.org", 
                    "last_name": "Payal Patel", 
                    "phone": "646-888-4359"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Maria C. Pietanza, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lgluck@ghs.org", 
                    "last_name": "William L Gluck, MD", 
                    "phone": "864-232-2820"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Greenville Health System, Clinical Research Unit, Institute for Translational Oncology Research"
                }, 
                "investigator": {
                    "last_name": "William L Gluck, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Spigel, MD", 
                    "phone": "615-329-7274"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology, PLLC"
                }, 
                "investigator": {
                    "last_name": "David Spigel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "melanie.herrin@usoncology.com", 
                    "last_name": "Melanie Herrin", 
                    "phone": "703-208-3188"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "Virginia Cancer Specialists"
                }, 
                "investigator": {
                    "last_name": "Alexander I. Spira, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)", 
        "overall_contact": {
            "email": "jakob.dupont@oncomed.com", 
            "last_name": "Jakob Dupont, MA, MD", 
            "phone": "650-995-8307"
        }, 
        "overall_official": {
            "affiliation": "Florida Cancer Specialists & Research Institute", 
            "last_name": "Lowell L. Hart, M.D., F.A.C.P.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The maximum tolerated dose (MTD) will be determined in patients treated with OMP-59R5 in combination with etoposide and cisplatin", 
                "measure": "Dose limiting toxicities (DLT) of OMP-59R5 in combination with Etoposide and Cisplatin", 
                "safety_issue": "Yes", 
                "time_frame": "Subjects will be treated and observed for DLT through the end of the first cycle (28 days)"
            }, 
            {
                "description": "To determine the clinical benefit, as measured by progression free survival of the addition OMP-59R5 to etoposide and cisplatin in subjects who are receiving first-line therapy for extensive stage small cell lung cancer", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Number of days from randomization until death or disease progression, assessed up 25 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859741"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK of OMP-59R5 when given in combination with etoposide and cisplatin. Plasma samples from all subjects enrolled in Phase 1 b portion of the study will be obtained for PK analysis at pre-infusion, approximately 5 minutes post infusion on Day 1 of cycles 1 and 3, and Day 8 of cycles 1 and 3 as well as when the subject is terminated from study treatment of OMP-59R5.  Pharmacokinetic parameters (i.e. area under the curve [AUC], clearance, volume of distribution and apparent half life) of OMP-59R5 will be assessed for each evaluable subject.", 
                "measure": "PK of OMP-59R5 when given in combination with Etoposide and Cisplatin.", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 3 and 8 of Cycle 1 and 3, and treatment termination"
            }, 
            {
                "description": "Survival status, anti-cancer treatment during the survival follow-up after the treatment termination, overall response at each tumor assessment", 
                "measure": "Overall survival, 12 month OS and overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study, and approximately every 6 weeks after the treatment termination"
            }, 
            {
                "description": "AEs, laboratory assessment and physical examination.", 
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Every 3 weeks till the patient comes off the study treatment, up to 25 months"
            }
        ], 
        "source": "OncoMed Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OncoMed Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}